NCT07091630View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

PHASE3RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

September 16, 2025

Primary Completion Date

October 7, 2027

Study Completion Date

January 23, 2031

Conditions
Chronic Inflammatory Demyelinating PolyneuropathyCIDPChronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
BIOLOGICAL

Empasiprubart IV

Intravenous infusion of empasiprubart

OTHER

Placebo IV

Intravenous infusion of placebo

Trial Locations (1)

77094

RECRUITING

NeuroCarePlus, Houston

Sponsors

Lead Sponsor

argenx
All Listed Sponsors
lead

argenx

INDUSTRY